SKU : MC549861
CAS Number : 343-27-1
Molecular Formula : C13H13ClN2O | Molecular Weight : 248.71
Synonyms : Telepathine (hydrochloride)
Quote RequestPurity | NLT 98% |
---|---|
Storage | at 20ºC 2 years |
* The above information is for reference only.
* If the product has intellectual property rights, a license granted is must or contact us.
Chemical Name | Harmine (hydrochloride) |
---|---|
CAS Number | 343-27-1 |
Molecular Formula | C13H13ClN2O |
Molecular Weight | 248.71 |
Synonyms | Telepathine (hydrochloride) |
Harmine Hydrochloride (Telepathine Hydrochloride) is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM[1]. IC50 & Target: Ki: 397 nM (5-HT2A serotonin receptor)[1], DYRK1A[2] In Vitro: Harmine inhibits tau phosphorylation by DYRK1A by selected DANDYs, with an IC50 of 190 nM[2]. Harmine negatively regulates homologous recombination (HR) by interfering Rad51 recruitment, resulting in severe cytotoxicity in hepatoma cells. Furthermore, NHEJ inhibitor Nu7441 markedly sensitizes Hep3B cells to the anti-proliferative effects of Harmine[3]. In Vivo: It is shown that brain water content is significantly increased in the TBI group. Treatment with Harmine significantly reduces the tissue water content at 1, 3 and 5 days, compared with the TBI group. Harmine treatment significantly reduces the escape latency at 3 and 5 days, compared with the TBI group. Post-TBI administration of Harmine significantly improves the motor function recovery of the rats at 1, 3 and 5 days following TBI, compared with the TBI group without Harmine treatment. The neuronal survival rate in the Harmine-treated group is significantly increased, compared with the TBI group. Administration of Harmine results in marked elevation in the expression of GLT-1, compared with the TBI group. The administration of Harmine significantly reduces the expression of caspase 3, compared with the TBI group[4].
© Copyright 2015-2024 Hangzhou MolCore BioPharmatech Co.,Ltd. All rights reserved.